BeiGene (ONC) said Thursday that it will discontinue the development of ociperlimab for lung cancer after an independent review panel recommended that the trial be stopped because the potential treatment was unlikely to improve survival outcomes.
BeiGene said no new safety concerns were identified during the trial.
Shares of the company were down 1.7% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.